Skip to main content
SpringerLink
Log in

Where the money is

  • News Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

It was US investors that largely bankrolled the biotech industry over the past 25 years. Is all that about to change? Michael Fitzgerald investigates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: The amount of capital raised by biotech through IPOs over the past ten years.
Figure 2: The amount of capital raised by biotech through follow-on offerings over the past ten years.

Author information

Authors and Affiliations

  1. Boston

    Michael Fitzgerald

Authors
  1. Michael Fitzgerald
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fitzgerald, M. Where the money is. Nat Biotechnol 24, 240–242 (2006). https://doi.org/10.1038/nbt0306-240

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0306-240

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation